Your browser is no longer supported. Please, upgrade your browser.
Settings
IONS Ionis Pharmaceuticals, Inc. daily Stock Chart
IONS [NASD]
Ionis Pharmaceuticals, Inc.
Index- P/E87.49 EPS (ttm)0.69 Insider Own0.10% Shs Outstand142.04M Perf Week-4.40%
Market Cap8.53B Forward P/E275.32 EPS next Y0.22 Insider Trans-33.74% Shs Float127.95M Perf Month-3.21%
Income97.70M PEG1.79 EPS next Q1.03 Inst Own88.10% Short Float6.63% Perf Quarter7.58%
Sales821.00M P/S10.38 EPS this Y-151.00% Inst Trans-0.15% Short Ratio8.49 Perf Half Y-12.86%
Book/sh9.51 P/B6.31 EPS next Y-87.67% ROA15.20% Target Price68.41 Perf Year3.43%
Cash/sh15.64 P/C3.84 EPS next 5Y49.00% ROE35.40% 52W Range53.34 - 86.58 Perf YTD-0.65%
Dividend- P/FCF53.69 EPS past 5Y4.50% ROI-6.00% 52W High-30.68% Beta2.00
Dividend %- Quick Ratio10.30 Sales past 5Y32.40% Gross Margin99.40% 52W Low12.52% ATR1.68
Employees737 Current Ratio10.40 Sales Q/Q15.50% Oper. Margin14.10% RSI (14)43.24 Volatility3.18% 2.32%
OptionableYes Debt/Eq0.00 EPS Q/Q673.50% Profit Margin52.30% Rel Volume1.71 Prev Close60.13
ShortableYes LT Debt/Eq0.49 EarningsFeb 05 BMO Payout0.00% Avg Volume998.81K Price60.02
Recom2.70 SMA20-2.52% SMA50-2.10% SMA200-7.17% Volume1,704,190 Change-0.18%
Dec-13-19Initiated Oppenheimer Outperform
Nov-13-19Initiated BofA/Merrill Buy $70
Nov-07-19Downgrade Morgan Stanley Equal-Weight → Underweight $63 → $48
Sep-10-19Upgrade Bernstein Mkt Perform → Outperform
Aug-08-18Reiterated Stifel Hold $48 → $47
Aug-07-18Reiterated Stifel Hold $55 → $48
May-08-18Downgrade Evercore ISI Outperform → In-line
Oct-06-17Resumed Goldman Sell $30
Aug-17-17Initiated Evercore ISI Outperform $65
Aug-09-17Reiterated Stifel Hold $42 → $50
Mar-10-17Downgrade Goldman Neutral → Sell
Dec-28-16Reiterated BMO Capital Markets Outperform $61 → $68
Dec-27-16Reiterated Leerink Partners Mkt Perform $40 → $47
Dec-27-16Reiterated Laidlaw Buy $59 → $65
Nov-10-16Resumed Leerink Partners Mkt Perform
Aug-10-16Reiterated Piper Jaffray Overweight $36 → $46
Aug-03-16Initiated Morgan Stanley Equal-Weight $37
Aug-02-16Reiterated Needham Buy $55 → $64
Aug-02-16Reiterated Barclays Equal Weight $26 → $41
May-27-16Reiterated Needham Buy $88 → $55
Jan-16-20 05:00AM  Top Picks 2020- Ionis Pharmaceuticals IONS MoneyShow
Jan-13-20 01:02PM  5 Health Care Stocks Gurus Are Buying GuruFocus.com
Jan-12-20 03:39PM  How Did Ionis Pharmaceuticals, Inc. (IONS) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Jan-10-20 07:00AM  Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy GlobeNewswire
Jan-09-20 07:05AM  Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer PR Newswire
07:00AM  Johnson & Johnson spinout signs licensing, collaboration deal worth up to $1.4B American City Business Journals
Jan-07-20 12:14PM  /C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./ PR Newswire
Jan-06-20 07:05AM  Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference PR Newswire
Jan-02-20 08:00AM  New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease GlobeNewswire
Dec-31-19 06:10AM  Experts question Cambridge biotech's strategy after trial failure American City Business Journals
Dec-24-19 09:27AM  Why Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Looks Like A Quality Company Simply Wall St.
07:00AM  Heres to Your Health: A Decade of Drug Breakthroughs Bloomberg
Dec-19-19 07:05AM  Ionis licenses investigational Alzheimer's therapy PR Newswire
Dec-18-19 10:03PM  Akcea Retains Rights to AKCEA-APOCIII-LRx GlobeNewswire
07:05AM  Ionis appoints C. Frank Bennett, Ph.D., to chief scientific officer and promotes Eric E. Swayze, Ph.D., to senior vice president of research PR Newswire
Dec-16-19 11:34PM  Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial PR Newswire
Dec-12-19 03:19PM  ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study Zacks
07:05AM  Ionis Pharmaceuticals announces private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024 PR Newswire
Dec-06-19 11:33AM  Hedge Funds Have Never Been This Bullish On Ionis Pharmaceuticals, Inc. (IONS) Insider Monkey
Dec-04-19 07:00AM  Akcea Announces Appointment of New Chief Operating Officer GlobeNewswire
Dec-02-19 07:05AM  Ionis Pharmaceuticals to hold technology webcast PR Newswire
Nov-25-19 07:00AM  Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis GlobeNewswire
Nov-20-19 10:20AM  Surging Earnings Estimates Signal Upside for Ionis Pharmaceuticals (IONS) Stock Zacks
07:25AM  The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Benzinga
Nov-19-19 04:05PM  Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx) GlobeNewswire
Nov-18-19 12:00PM  Antisense Therapeutics Announces Additional preliminary data from the ATL1102 Phase II DMD trial presented at the 2019 Action Duchenne International Conference PR Newswire
11:11AM  Estimating The Fair Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Simply Wall St.
Nov-13-19 01:25AM  Edited Transcript of IONS earnings conference call or presentation 6-Nov-19 4:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 07:05AM  Ionis Pharmaceuticals to present at upcoming investor conferences PR Newswire
Nov-06-19 04:14PM  Here's One Drugmaker That Popped On Earnings And Two That Didn't Investor's Business Daily
08:35AM  Ionis Pharmaceuticals (IONS) Q3 Earnings and Revenues Beat Estimates Zacks
07:00AM  Ionis provides third quarter financial results and improved 2019 guidance PR Newswire
Oct-30-19 10:34AM  Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
Oct-28-19 07:05AM  Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference PR Newswire
Oct-25-19 08:37AM  Ionis Pharmaceuticals Enters Oversold Territory Zacks
Oct-23-19 07:05AM  Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences PR Newswire
Oct-22-19 07:05AM  Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast PR Newswire
07:00AM  Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast GlobeNewswire
Oct-20-19 03:03PM  Is Ionis Pharmaceuticals, Inc. (IONS) A Good Stock To Buy? Insider Monkey
Oct-10-19 08:00AM  Ionis Jumps After Vote of Confidence in Drug Pipeline TheStreet.com
07:05AM  Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting PR Newswire
Oct-09-19 11:18AM  Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates Zacks
06:50AM  Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results PR Newswire
Oct-07-19 04:13PM  How A Deal With Pfizer Sent This Pharma Stock Rocketing In High Volume Investor's Business Daily
10:57AM  Does Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Pay Compare Well With Peers? Simply Wall St.
06:50AM  Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx) GlobeNewswire
Oct-01-19 06:31AM  With eyes on IPO, muscular dystrophy startup names new CEO American City Business Journals
Sep-26-19 11:32AM  Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN Zacks
Sep-25-19 10:05AM  Ionis to receive the CLSA's 2019 Pantheon DiNA Award for Company of the Year PR Newswire
Sep-23-19 09:43AM  Akcea's stock drops after 3 top executives leave company, including CEO MarketWatch
09:40AM  Akcea Therapeutics shakes up executive suite, board in 'disconcerting' move American City Business Journals
Sep-19-19 11:30AM  Biogen's New Study to Test Higher Dose of SMA Drug Spinraza Zacks
Sep-18-19 07:30AM  Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients GlobeNewswire
Sep-17-19 10:23PM  Positive preliminary results from ATL1102 for DMD Phase II trial PR Newswire
Sep-16-19 07:00AM  Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting GlobeNewswire
Sep-05-19 09:17AM  If You Had Bought Ionis Pharmaceuticals (NASDAQ:IONS) Shares Three Years Ago You'd Have Made 107% Simply Wall St.
Sep-03-19 08:01AM  How Biotech Companies Are Targeting RNA to Cure Diseases Barrons.com
Aug-29-19 07:00AM  Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings GlobeNewswire
Aug-28-19 02:15PM  Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo Zacks
07:05AM  Ionis Pharmaceuticals to present at upcoming investor conferences PR Newswire
Aug-27-19 07:05AM  Ionis licenses hepatitis B program to GSK PR Newswire
Aug-22-19 08:15PM  Ionis Pharmaceuticals Inc (IONS) Chairman and CEO Stanley T Crooke Sold $1.6 million of Shares GuruFocus.com -5.96%
Aug-15-19 03:50PM  Ionis Pharmaceuticals, Inc. (IONS) Q2 2019 Earnings Call Transcript Motley Fool
Aug-14-19 01:47PM  Ionis Pharmaceuticals Looks to Partners to Pay the Bills Motley Fool
09:15AM  Market Takes Off After Tariffs Pushed Back Zacks
09:13AM  Edited Transcript of IONS earnings conference call or presentation 7-Aug-19 3:30pm GMT Thomson Reuters StreetEvents
08:53AM  3 Charts That Suggest Now Is the Time to Buy Into Biotech Investopedia
Aug-07-19 05:10PM  New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome GlobeNewswire +5.63%
08:15AM  Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:34AM  The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout Benzinga
07:00AM  Ionis Reports Second Quarter 2019 Financial Results PR Newswire
Aug-06-19 04:05PM  Akcea Reports Financial Results and Highlights for Second Quarter 2019 GlobeNewswire
04:05PM  Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy GlobeNewswire
08:54AM  Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet? Simply Wall St.
Jul-31-19 10:36AM  Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for Zacks
09:15AM  Rate Cut Wait Almost Over Zacks
Jul-30-19 10:38AM  Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for Zacks
07:05AM  Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast PR Newswire
Jul-22-19 08:15PM  Ionis Pharmaceuticals Inc (IONS) Chairman & CEO Stanley T Crooke Sold $702,500 of Shares GuruFocus.com
Jul-19-19 06:00AM  Ionis Pharmaceuticals IONS- 2019 Top Picks' Mid-Year Update MoneyShow
Jul-10-19 09:15AM  Late Surge Helps S&P Join NASDAQ in the Green Zacks
Jul-01-19 07:30AM  Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients PR Newswire
07:30AM  Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients GlobeNewswire
Jun-30-19 12:15PM  3 Top Biotech Stocks to Add to Your Watchlist Motley Fool
Jun-29-19 04:00AM  Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy GlobeNewswire
Jun-21-19 12:13PM  Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) A High Quality Stock To Own? Simply Wall St.
Jun-20-19 04:38PM  Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting GlobeNewswire
Jun-18-19 07:05AM  Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference PR Newswire
Jun-12-19 04:05PM  Ionis announces appointment of Joan E. Herman to its board of directors PR Newswire
Jun-11-19 07:26AM  Are Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Paying Above The Intrinsic Value? Simply Wall St.
Jun-06-19 07:05AM  Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders PR Newswire
Jun-03-19 12:18PM  Here's Why Mirati Therapeutics Is Jumping Today Motley Fool
May-28-19 07:00AM  Akcea Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-27-19 11:10AM  Novartis Gene Therapy Crosses The $2 Million Mark Will Others Follow? Investor's Business Daily
May-25-19 10:19AM  What Is Nektar Therapeutics' New Game Plan? Motley Fool
May-24-19 07:46PM  Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio Motley Fool
May-20-19 09:35PM  Edited Transcript of IONS earnings conference call or presentation 9-May-19 3:30pm GMT Thomson Reuters StreetEvents
12:04PM  Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock InvestorPlace
09:49AM  7 A-Rated Healthcare Stocks for Industry Expansion InvestorPlace
May-14-19 07:02PM  Biogens SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy GlobeNewswire
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CROOKE STANLEY TExecutive Chairman of BoardJan 15Option Exercise0.003,31708,849Jan 17 06:28 PM
CROOKE STANLEY TExecutive Chairman of BoardJan 15Option Exercise0.0039,6430109,277Jan 17 06:28 PM
BENNETT C FRANKChief Scientific OfficerJan 15Option Exercise0.0011,711036,357Jan 17 06:11 PM
Geary Richard SSVP, DevelopmentJan 15Option Exercise0.0013,139034,722Jan 17 06:30 PM
HOUGEN ELIZABETH LSVP, Finance & CFOJan 15Option Exercise0.0012,044036,504Jan 17 06:33 PM
Monia Brett PChief Executive OfficerJan 15Option Exercise0.0019,921036,206Jan 17 06:36 PM
O'NEIL PATRICK R.SVP, Legal & General CounselJan 15Option Exercise0.0012,045028,879Jan 17 06:39 PM
PARSHALL B LYNNEDirectorJan 15Option Exercise0.0015,136068,702Jan 17 06:42 PM
Swayze EricSVP, ResearchJan 15Option Exercise0.006,52207,290Jan 17 06:47 PM
Monia Brett PChief Executive OfficerJan 02Sale60.2517310,42316,285Jan 03 07:04 PM
KLEIN JOSEPH IIIDirectorDec 23Option Exercise35.531,00035,53013,683Dec 23 07:28 PM
KLEIN JOSEPH IIIDirectorDec 23Sale61.871,00061,87412,683Dec 23 07:28 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 20Option Exercise10.8210,634115,06027,251Dec 20 07:23 PM
KLEIN JOSEPH IIIDirectorDec 16Option Exercise35.531,00035,53013,683Dec 18 05:07 PM
KLEIN JOSEPH IIIDirectorDec 16Sale65.451,00065,44712,683Dec 18 05:07 PM
KLEIN JOSEPH IIIDirectorDec 09Option Exercise35.531,00035,53013,683Dec 10 06:54 PM
KLEIN JOSEPH IIIDirectorDec 09Sale63.741,00063,74512,683Dec 10 06:54 PM
Geary Richard SSVP, DevelopmentDec 04Option Exercise14.6910,000146,90031,583Dec 05 05:26 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 04Option Exercise10.824,56649,40424,117Dec 05 05:31 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 04Sale65.004,566296,79020,055Dec 05 05:31 PM
Geary Richard SSVP, DevelopmentDec 04Sale65.0010,000650,00021,583Dec 05 05:26 PM
Geary Richard SSVP, DevelopmentDec 02Option Exercise14.695,00073,45026,583Dec 04 06:22 PM
KLEIN JOSEPH IIIDirectorDec 02Option Exercise35.531,00035,53013,683Dec 04 06:26 PM
KLEIN JOSEPH IIIDirectorDec 02Sale64.081,00064,08312,683Dec 04 06:26 PM
Geary Richard SSVP, DevelopmentDec 02Sale65.065,000325,28721,583Dec 04 06:22 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 25Option Exercise10.824,00043,28024,055Nov 26 05:40 PM
KLEIN JOSEPH IIIDirectorNov 25Sale62.9081251,07512,683Nov 26 05:43 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 25Sale62.504,000250,00020,055Nov 26 05:40 PM
KLEIN JOSEPH IIIDirectorNov 20Sale60.002,000120,00013,495Nov 21 06:40 PM
Monia Brett PCOO & SVP, Translational MedNov 20Sale60.015,776346,61816,458Nov 21 06:38 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 19Option Exercise10.824,00043,28024,055Nov 21 06:36 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 19Sale58.804,000235,20020,055Nov 21 06:36 PM
Hayden Michael RDirectorOct 15Option Exercise0.001,77801,778Oct 17 05:52 PM
Reikes Peter NDirectorOct 15Option Exercise0.001,77801,778Oct 17 05:15 PM
CROOKE STANLEY TChairman and CEOAug 21Option Exercise39.8710,000398,70079,634Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 21Sale72.1510,000721,50069,634Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 20Option Exercise39.872,00079,7407,532Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 20Option Exercise39.8710,000398,70079,634Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 20Sale71.002,000142,0005,532Aug 22 06:41 PM
CROOKE STANLEY TChairman and CEOAug 20Sale71.0010,000710,00069,634Aug 22 06:41 PM
CROOKE STANLEY TChairman & CEOJul 18Option Exercise39.8710,000398,70079,634Jul 22 05:34 PM
CROOKE STANLEY TChairman & CEOJul 18Sale70.2510,000702,50669,634Jul 22 05:34 PM
McDevitt DamienChief Business OfficerJul 15Option Exercise0.003,54203,798Jul 17 05:39 PM
KLEIN JOSEPH IIIDirectorJul 03Option Exercise0.00667015,495Jul 03 06:46 PM
MUTO FREDERICK TDirectorJul 03Option Exercise0.00667012,683Jul 03 06:43 PM
LOSCALZO JOSEPHDirectorJul 03Option Exercise0.00667013,308Jul 03 06:39 PM
WENDER JOSEPH HDirectorJul 03Option Exercise0.00667061,805Jul 03 06:34 PM
PARSHALL B LYNNEDirectorJul 02Option Exercise0.00889053,566Jul 03 06:49 PM
KLEIN JOSEPH IIIDirectorJul 02Option Exercise0.00889014,828Jul 03 06:46 PM
MUTO FREDERICK TDirectorJul 02Option Exercise0.00889012,016Jul 03 06:43 PM
LOSCALZO JOSEPHDirectorJul 02Option Exercise0.00889012,641Jul 03 06:39 PM
WENDER JOSEPH HDirectorJul 02Option Exercise0.00889061,138Jul 03 06:34 PM
Monia Brett PChief Operating OfficerJul 02Sale66.4021013,94422,234Jul 02 08:50 PM
KLEIN JOSEPH IIIDirectorJul 01Option Exercise0.001,333013,939Jul 03 06:46 PM
MUTO FREDERICK TDirectorJul 01Option Exercise0.001,333011,127Jul 03 06:43 PM
LOSCALZO JOSEPHDirectorJul 01Option Exercise0.001,333011,752Jul 03 06:39 PM
WENDER JOSEPH HDirectorJul 01Option Exercise0.001,333060,249Jul 03 06:34 PM
BERTHELSEN SPENCER RDirectorJun 24Option Exercise16.3215,000244,800103,784Jun 26 06:52 PM
BERTHELSEN SPENCER RDirectorJun 24Sale63.6715,000955,11394,094Jun 26 06:52 PM
MUTO FREDERICK TDirectorJun 04Option Exercise16.3215,000244,80024,794Jun 06 06:35 PM
MUTO FREDERICK TDirectorJun 04Sale65.2915,000979,3509,794Jun 06 06:35 PM
MUTO FREDERICK TDirectorMay 06Option Exercise24.428,000195,36017,794May 08 06:16 PM
MUTO FREDERICK TDirectorMay 06Sale72.758,000582,0029,794May 08 06:16 PM
PARSHALL B LYNNEDirectorApr 29Option Exercise39.8750,0001,993,500102,677May 01 05:48 PM
PARSHALL B LYNNEDirectorApr 29Sale75.0150,0003,750,63552,677May 01 05:48 PM
CROOKE STANLEY TChairman and CEOApr 16Option Exercise31.161,00031,1556,232Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 16Option Exercise31.4620,000629,19882,954Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 16Sale84.751,00084,7505,532Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 16Sale84.6220,0001,692,50069,634Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 15Option Exercise10.821,00010,8206,532Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 15Option Exercise14.6910,000146,90079,634Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 15Sale85.251,00085,2505,532Apr 17 07:30 PM
CROOKE STANLEY TChairman and CEOApr 15Sale85.2510,000852,50069,634Apr 17 07:30 PM
Geary Richard SSVP, DevelopmentApr 08Option Exercise42.5346,2401,966,46645,442Apr 10 06:24 PM
Geary Richard SSVP, DevelopmentApr 08Sale84.0146,2403,884,75321,442Apr 10 06:24 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 05Option Exercise61.682,252138,90318,925Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 05Sale84.752,252190,85716,673Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 04Option Exercise56.7636,6222,078,80935,165Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 04Sale83.7939,6223,319,92916,673Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 03Option Exercise61.687,654472,09927,327Apr 05 07:29 PM
O'NEIL PATRICK R.SVP Legal & General CounselApr 03Sale84.837,654649,28919,673Apr 05 07:29 PM
WENDER JOSEPH HDirectorMar 19Sale79.6310,000796,25858,916Mar 20 06:05 PM
O'NEIL PATRICK R.SVP Legal & General CounselMar 18Option Exercise61.5728,8001,773,21648,473Mar 20 06:15 PM
O'NEIL PATRICK R.SVP Legal & General CounselMar 18Sale78.7928,8002,269,18719,673Mar 20 06:15 PM
PARSHALL B LYNNEDirectorMar 12Option Exercise39.878,334332,27761,011Mar 14 06:24 PM
PARSHALL B LYNNEDirectorMar 12Sale75.008,334625,05052,677Mar 14 06:24 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 27Option Exercise45.1126,8001,208,95233,773Mar 01 05:40 PM
PARSHALL B LYNNEDirectorFeb 27Option Exercise39.878,333332,23761,010Mar 01 05:56 PM
PARSHALL B LYNNEDirectorFeb 27Sale70.008,333583,31052,677Mar 01 05:56 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 27Sale68.0126,8001,822,58019,673Mar 01 05:40 PM
CROOKE STANLEY TChairman and CEOFeb 26Option Exercise39.8737,0001,475,190106,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 26Sale61.5437,0002,276,79969,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 25Option Exercise39.8740,0001,594,800109,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 25Sale60.0740,0002,402,70069,634Feb 27 07:31 PM
CROOKE STANLEY TChairman and CEOFeb 13Option Exercise33.126,904228,66610,832Feb 14 05:57 PM
CROOKE STANLEY TChairman and CEOFeb 13Option Exercise39.8740,0001,594,800109,634Feb 14 05:57 PM
Geary Richard SSVP, DevelopmentFeb 13Sale60.0099959,94021,442Feb 14 05:51 PM
CROOKE STANLEY TChairman and CEOFeb 13Sale60.006,904414,2405,532Feb 14 05:57 PM
CROOKE STANLEY TChairman and CEOFeb 13Sale60.1040,0002,404,02869,634Feb 14 05:57 PM
O'NEIL PATRICK R.SVP Legal & General CounselFeb 12Option Exercise39.8727510,96419,948Feb 14 06:01 PM